European Launch of ResistancePlus MG FleXible for the GeneXpert System
16.12.2019 10:00:00 EET | Business Wire | Press release
SpeeDx Pty, Ltd. today announced the European launch of Resistance Plus® MG FleXible, the first sample-to-answer test for detecting the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance. Cepheid is the exclusive distribution partner of this test, available through Cepheid’s FleXible Cartridge programme for the GeneXpert System.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191215005039/en/
ResistancePlus MG FleXible is now selling in France and the U.K. (to be followed by rest of EU, Australia and New Zealand). This successful collaboration between SpeeDx and Cepheid is the first sample-to-answer test for Mgen and macrolide resistance - exclusively distributed by Cepheid. (Photo: Business Wire)
Management guidelines around the world, including those recently updated in France1 and the U.K.2, reference testing the macrolide resistance status of Mgen infections in order to more effectively treat patients. Mgen can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease, and has been linked to reproductive health complications including pre-term birth and infertility.2,3 Due to the challenges of rising antimicrobial resistance and a lack of clear data that asymptomatic infection leads to protracted health complications, Mgen testing guidelines are unanimous in their recommendation to only test symptomatic individuals.
“This is an important test expansion for the thousands of GeneXpert Systems on the market,” said Colin Denver, SpeeDx CEO. “ Resistance Plus MG FleXible enables Resistance Guided Therapy, supporting more clinicians to adhere to testing guidelines and maximising effective care for their patients infected with Mgen.”
Both SpeeDx and Cepheid will be showcasing Resistance Plus MG at RICAI (Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse) December 15th and 16th in Paris. Visit SpeeDx booth #41bis and Cepheid booth #18 to learn more.
About SpeeDx
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. The SpeeDx Resistance Plus® MG open-platform assay is CE marked for sale in Europe, TGA approved for sale in Australia and clinical trials are being finalised for submission to the U.S. FDA. Products in the SpeeDx portfolio focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
For more information on SpeeDx please see: https://plexpcr.com
- https://www.sfdermato.org/site/groupe-infectiologie-dermatologique-et-infections-sexuellement-transmissibles.html
- https://www.bashhguidelines.org/media/1146/ngu-update-05_2017-final.pdf
- http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191215005039/en/
Contact information
SpeeDx:
Europe, Australia, New Zealand:
Madeline O’Donoghue
+61 2 9209 4170
madelineo@speedx.com.au
Cepheid:
Darwa Peterson
darwa@cepheid.com
Tel. + 1.408.400.4324
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation Opens New Melbourne Service Facility at Essendon Fields Airport, Expanding Support for Cessna, Beechcraft and Hawker Customers in APAC5.5.2026 18:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced its new service facility at Essendon Fields Airport in Melbourne is now open for customers, expanding factory-direct support for Cessna, Beechcraft and Hawker customers across Australia and the Asia-Pacific region. The purpose-built facility strengthens Textron Aviation’s global service network and reflects the company’s long-term commitment to expanding capacity and enhancing customer support throughout aircraft ownership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505135152/en/ Textron Aviation opens new Melbourne service facility at Essendon Fields airport, expanding support for Cessna, Beechcraft and Hawker customers in APAC “We’ve supported customers in Australia for decades, and we continue to invest where our customers tell us they need more capacity and faster access to factory direct expertise,” said Brian Rohloff, senior vice presiden
Doha Debates Podcast Examines the Global Questions Shaping Society5.5.2026 17:37:00 EEST | Press release
Qatar Foundation’s Doha Debates continues the rollout of its weekly Doha Debates Podcast episodes, airing every Tuesday through June 2. Since launching on January 6, the season has brought leading global thinkers into direct conversation on the defining questions of our time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299576/en/ Doha Debates podcast examines the global questions shaping society. Weekly Tuesday releases from January 6 through June 2 extend conversations from Doha Debates’ flagship debates and global town halls. (Photo: AETOSWire) The Doha Debates Podcast extends themes first explored in Doha Debates’ flagship debates and town halls, offering deeper, sustained exchanges that connect disciplines, regions and worldviews through open, truth-seeking dialogue. The latest episode, “Do conspiracy theories have any value?”, moderated by Dareen Abughaida, brings together Heather Berlin, Alex Berenson, Nuurria
INRIX Unveils Global Standard for Traffic Signal Intelligence5.5.2026 17:34:00 EEST | Press release
INRIX, a global leader in transportation analytics and mobility intelligence, today announced a series of major updates to its award-winning Signal AnalyticsTM platform. These updates deliver unprecedented scale, statistical confidence, and flexibility by combining INRIX’s proven signal performance methodology with newly integrated traffic data, creating the most comprehensive, data-richsignal analytics solution to date. “INRIX Signal Analytics saves hours of monitoring every week by identifying where problems exist and enabling data-driven decisions that improve efficiency and safety at our intersections. It has been a valuable tool for optimizing our signal operations,” said Aaron M Torres, Traffic Operations Manager, Osceola County, Florida. With these updates, transportation agencies can now monitor, diagnose, and improve signalized intersections without installing hardware, deploying sensors, or changing existing workflows. Built on more than five years of continuous innovation an
Convatec’s Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 20265.5.2026 17:11:00 EEST | Press release
Convatec, a leading medical products and technology company focused on chronic condition management, takes to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026. Convatec’s industry-leading Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal wounds across foam, multimodal, nitric oxide‑generating dressings, antimicrobial technology and Wound Hygiene. Convatec has launched or secured approvals for five new wound care products since 2022, demonstrating our commitment to pioneering innovative solutions to support patients and healthcare professionals, including: ConvaFoam™: Best-in-class multi-layer foam dressing designed to be repositionable on appli
Laserfiche Recognized as a Leader in 2026 Gartner® Magic Quadrant™ for Document Management5.5.2026 17:00:00 EEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management — has been positioned as a Leader in the 2026 Magic Quadrant for Document Management. Laserfiche believes this recognition underscores the company’s commitment to empowering organizations to transform complex, operational business processes through AI-powered content management. “It’s incredible to see Laserfiche recognized during the same week as our annual Empower conference, where we announced our latest agentic AI capabilities,” said Thomas Phelps, senior vice president of corporate strategy and chief information officer at Laserfiche. “We believe being positioned as a Leader — and receiving the highest overall rating among 16 vendors in Gartner Peer Insights, with a 4.7 out of 5.0 based on over 1,300 reviews as of April 30, 2026 — reflects our relentless focus on product innovation and delivering value to our customers.” As the document management market continues to evolve and expand, the ability to bridge t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom